Nonsurgical oncological management of cancer pain

Gough, Nicholas; Miah, Aisha; Linch, Mark

doi:10.1097/spc.0000000000000043

Cited by 21 publications

(13 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10,22,63,71,79,112 Conversely, spontaneous pain (without specific eliciting stimuli) and evoked pain (ie, in response to standing, weight-bearing, movement, touch, or other stimuli) associated with CIBP are difficult to treat from the onset because of their intermittent nature, which tends to be very rapid in onset, intense, and of short duration. 10,22,63,71,79,112 Terminology commonly used in the clinical setting to describe evoked or spontaneous pain include breakthrough pain, incident pain, or a pain flare; however, definitions for these terms often lack precision and may overlap. For example, breakthrough pain is defined as a transitory flare of pain in the setting of chronic pain managed with opioid drugs, 127 yet the evoked pain seen in CIBP can occur during weight-bearing without current opioid use.…”

Section: Resultsmentioning

confidence: 99%

AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions

Paice¹,

Mulvey

Bennett

et al. 2017

The Journal of Pain

View full text Add to dashboard Cite

Chronic cancer pain is a serious complication of malignancy or its treatment. Currently, no comprehensive, universally accepted cancer pain classification system exists. Clarity in classification of common cancer pain syndromes would improve clinical assessment and management. Moreover, an evidence-based taxonomy would enhance cancer pain research efforts by providing consistent diagnostic criteria, ensuring comparability across clinical trials. As part of a collaborative effort between the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) and the American Pain Society (APS), the ACTTION-APS Pain Taxonomy initiative worked to develop the characteristics of an optimal diagnostic system. After the establishment of these characteristics, a working group consisting of clinicians and clinical and basic scientists with expertise in cancer and cancer-related pain was convened to generate core diagnostic criteria for an illustrative sample of 3 chronic pain syndromes associated with cancer (ie, bone pain and pancreatic cancer pain as models of pain related to a tumor) or its treatment (ie, chemotherapy-induced peripheral neuropathy). A systematic review and synthesis was conducted to provide evidence for the dimensions that comprise this cancer pain taxonomy. Future efforts will subject these diagnostic categories and criteria to systematic empirical evaluation of their feasibility, reliability, and validity and extension to other cancer-related pain syndromes.

show abstract

Section: Resultsmentioning

confidence: 99%

AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions

Paice¹,

Mulvey

Bennett

et al. 2017

The Journal of Pain

View full text Add to dashboard Cite

show abstract

“…[46] However, various phase II and III trials found increased cardiovascular events from COX-2 inhibition, thereby tempering the enthusiasm for use of COX-2 inhibitors in cancer patients. [47, 48]…”

Section: 4 Therapeutic Management Of Cibpmentioning

confidence: 99%

“…They act on opioid G-protein coupled receptors (μ, κ, and δ), inhibiting substance P release in the dorsal horn. [47] Opiods are used by nearly 80% of cancer patients for pain control. Sustained and on-demand formulations are used in conjuction to provide pain suppression and breakthrough pain relief respectively.…”

Section: 4 Therapeutic Management Of Cibpmentioning

confidence: 99%

Bone Pain and Muscle Weakness in Cancer Patients

Milgrom

Lad

Koniaris

et al. 2017

Curr Osteoporos Rep

View full text Add to dashboard Cite

Purpose of review In this article we will discuss the current understanding of bone pain and muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms of cancer-induced bone pain (CIBP) and cancier-induced muscle wasting (CIMW), as well as current methods of diagnosis and treatment. We will discuss future therapies and research directions to help patients with these problems. Recent Findings There are several pharmacologic therapies that are currenly in pre-clinical and clinical testing that appear to be promising adjuncts to current CIBP and CIMW therapies. Such therapies include resiniferitoxin, which is a targeted inhibitor of nociptive nerve fibers, and selective androgen receptor modulators, which show promise in increasing lean mass. Summary CIBP and CIMW are a significant causes of morbidity in affected patients. Current management is mostly palliative; however, targeted therapies are poised to revolutionize how these problems are treated.

show abstract

“…Most cancer patients experience pain at some point during the course of their disease and approximately 25% die in pain . The prevalence of cancer pain has been reported to be approximately 60–85%, and is the most commonly reported symptom in cancer patients . One survey of more than 5000 adult cancer patients across multiple countries reported a pain prevalence of 84%, with 94% of those experiencing pain classifying it as moderate to severe and 43% classifying their pain as severe .…”

Section: Introductionmentioning

confidence: 99%